Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 ANI Appoints Regulatory Affairs VP | Contract Pharma

What are you searching for?

Sign in
Promotions & Moves

ANI Appoints Regulatory Affairs VP

Dr. Quinn brings more than 30 years of leadership experience in Global Regulatory Affairs

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Karen Quinn Ph.D. has been appointed vice president Corticotropin Regulatory Affairs at ANI Pharmaceuticals.

Dr. Quinn brings more than 30 years of leadership experience in Global Regulatory Affairs, specifically with a focus on drug products with biologically-derived active pharmaceutical ingredients. Dr. Quinn most recently served as senior director, Global Regulatory Affairs/CMC and head of the Biologics Group at Takeda Pharmaceuticals. She also held various global regulatory affairs positions with The Dow Chemical Company, Proctor & Gamble Pharmaceuticals, Solvay Pharmaceuticals, Wyeth Pharmaceuticals and Millennium Pharmaceuticals.

Arthur S. Przybyl, ANI’s president and chief executive officer, said, “I am pleased that Karen has joined ANI to help lead the advancement of our most exciting pipeline opportunity, which is the re-commercialization of our Corticotrophin NDAs.  ANI intends to continue to expand resources devoted to this project as we enter what is going to be a very important year for development of our Corticotropin products.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters